Accelerated Assessment Requests Fall Flat At EMA
Pharming Awaits Verdict On Leniolisib
Executive Summary
Very few companies asked the European Medicines Agency to fast track their drug marketing authorization applications in the first half of this year, and those that did were all turned down.
You may also be interested in...
EU Fast Track Sought For Epidermolysis Bullosa Gene Therapy & Bispecific RRMM Drug
Janssen and Krystal Biotech will soon learn whether the European Medicines Agency considers their respective products to be of potential major public health interest, particularly from the point of view of therapeutic innovation.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.